We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High-Throughput siRNA Screening Identifies Drug Targets in MYC-driven Cancers

By LabMedica International staff writers
Posted on 04 Jun 2012
Print article
A sophisticated high-throughput screening technique was used to search for genes able to block the activity of an oncogene that produces a protein that had traditionally been considered “undruggable” due to its lack of binding sites for low molecular weight inhibitors.

Investigators at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) focused their attention on the gene MYC, which is a strong protooncogene that it is very often found to be upregulated in many types of cancers. The Myc protein encoded by this gene is a transcription factor that activates expression of a great number of genes through binding on consensus sequences (Enhancer Box sequences (E-boxes)) and recruiting histone acetyltransferases (HATs). It can also act as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 coactivator, it inhibits expression of Miz-1 target genes. Myc is activated upon various mitogenic signals such as Wnt, Shh, and EGF (via the MAPK/ERK pathway). By modifying the expression of its target genes, MYC activation results in numerous biological effects. The protein encoded by MYC has been found to be highly resistant to chemotherapy mainly because it lacks efficient binding sites for drug compounds.

A paper published in the May 23, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA described the use of high-throughput siRNA (small interfering RNA) screening to evaluate a library of 3.300 druggable genes for their possible effect on MYC. Of 49 genes selected for follow-up, 48 were confirmed by independent retesting, and approximately one-third selectively induced accumulation of cellular DNA damage. In addition, genes involved in histone acetylation and transcriptional elongation were identified, indicating that the screen had revealed known MYC-associated pathways.

For in vivo validation in a nude mouse xenograft model, the investigators selected the enzyme CSNK1e, a kinase whose expression correlated with MYC amplification in neuroblastoma (an established MYC-driven cancer). Using RNAi and available small-molecule inhibitors, they confirmed that inhibition of CSNK1e halted growth of MYC-amplified neuroblastoma xenografts.

An inhibitor for CSNK1e already exists: a compound that originally was developed to modulate sleep cycles. “It had been sitting on a shelf for years, like the thousands of other “orphan” drugs that are abandoned when they prove ineffective for their intended use,” said senior author Dr. Carla Grandori, professor of human biology at the Fred Hutchinson Cancer Research Center. “Fortunately, MYC-driven cancer cells have an Achilles heel. Their rapid growth and division damages their DNA, and they rely on other genes to repair that damage. Disabling those genes can cripple the cancer’s ability to grow.”

“It is possible that the next great breakthrough in cancer therapy is already out there, sitting on a shelf, hiding in plain view,” said Dr. Grandori. “We have barely scratched the surface. These techniques are incredibly powerful, but they are new and not widely known. There are thousands of researchers who could apply this approach to their work. In the right hands, it could speed up the development of new cancer therapies a thousand-fold.”

Related Links:

Fred Hutchinson Cancer Research Center



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.